Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Extensive Stage Small Cell Lung Cancer|Hereditary Paraganglioma|Male Breast Cancer|Malignant Paraganglioma|Metastatic Gastrointestinal Carcinoid Tumor|Metastatic Pheochromocytoma|Pancreatic Polypeptide Tumor|Recurrent Breast Cancer|Recurrent Cervical Cancer|Recurrent Endometrial Carcinoma|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Islet Cell Carcinoma|Recurrent Neuroendocrine Carcinoma of the Skin|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Recurrent Pheochromocytoma|Recurrent Prostate Cancer|Recurrent Renal Cell Cancer|Recurrent Small Cell Lung Cancer|Recurrent Uterine Sarcoma|Regional Gastrointestinal Carcinoid Tumor|Regional Pheochromocytoma|Stage III Cervical Cancer|Stage III Endometrial Carcinoma|Stage III Neuroendocrine Carcinoma of the Skin|Stage III Ovarian Epithelial Cancer|Stage III Ovarian Germ Cell Tumor|Stage III Prostate Cancer|Stage III Renal Cell Cancer|Stage III Uterine Sarcoma|Stage IIIA Breast Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Breast Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Stage IV Endometrial Carcinoma|Stage IV Neuroendocrine Carcinoma of the Skin|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Ovarian Germ Cell Tumor|Stage IV Prostate Cancer|Stage IV Renal Cell Cancer|Stage IV Uterine Sarcoma|Stage IVA Cervical Cancer|Stage IVB Cervical Cancer|Thyroid Gland Medullary Carcinoma
Interventions: DRUG: temsirolimus|DRUG: vinorelbine ditartrate
Sponsor: University of Southern California
Collaborators: Wyeth is now a wholly owned subsidiary of Pfizer